Vir Biotechnology (VIR) Gross Margin (2020 - 2026)
Vir Biotechnology (VIR) posted Gross Margin of 99.09% for Q2 2025, down 0.91% sequentially from 100.0% in Q1 2025, and up 78.0% YoY from 55.67% in Q2 2024.
Powered by 
Analysis
Vir Biotechnology (VIR) Gross Margin (2020 - 2026) Analysis & Trends
Vir Biotechnology has reported Gross Margin for 6 years, with the latest figure at 99.09% in Q2 2025.
- Quarterly Gross Margin rose 78.0% year-over-year to 99.09% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 96.08% (down 264.0% YoY) and the FY2025 annual result came in at 99.96%, up 110.0% from the prior year.
- Gross Margin eased to 99.09% in Q2 2025 per VIR's latest filing, from 100.0% in the prior quarter.
- Over five years, Gross Margin peaked at 100.0% in Q1 2021 and troughed at 31.28% in Q2 2022.
- A 5-year average of 92.81% and a median of 97.44% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2023: Gross Margin tumbled 6804 bps in 2022, then soared 6814 bps in 2023.
- Over 5 years, Gross Margin stood at 93.0% in 2021, then declined by 6 bps to 87.86% in 2022, then climbed by 8 bps to 95.25% in 2023, then slipped by 1 bps to 94.47% in 2024, then climbed by 5 bps to 99.09% in 2025.
- According to Business Quant data, Gross Margin over the past three periods registered 99.09%, 100.0%, and 94.47% for Q2 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 84.20% |
| 10 | Vir Biotechnology | 1.93 Bn | 1.93 Bn | 238.95 Mn | 100.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 100.00% |
| Jun 30, 2025 | 99.09% |
| Mar 31, 2025 | 100.00% |
| Dec 31, 2024 | 94.47% |
| Sep 30, 2024 | 97.90% |
| Jun 30, 2024 | 98.31% |
| Mar 31, 2024 | 99.90% |
| Dec 31, 2023 | 95.25% |
| Sep 30, 2023 | 98.56% |
| Jun 30, 2023 | 99.42% |
| Mar 31, 2023 | 96.97% |
| Dec 31, 2022 | 87.86% |
| Sep 30, 2022 | 94.06% |
| Jun 30, 2022 | 31.28% |
| Mar 31, 2022 | 92.69% |
| Dec 31, 2021 | 93.00% |
| Sep 30, 2021 | 92.44% |
| Jun 30, 2021 | 99.35% |
| Mar 31, 2021 | 100.00% |
| Dec 31, 2020 | 100.00% |